These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2132185

  • 1. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 2. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP, Mathur S, Barradas MA, Dandona P.
    J Cardiovasc Pharmacol; 1990 Jul; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [Abstract] [Full Text] [Related]

  • 3. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 4. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN, Winocour PH, Bhatnagar D.
    J Cardiovasc Pharmacol; 1990 Nov; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [Abstract] [Full Text] [Related]

  • 5. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
    Alberti KG, Jones IR, Laker MF, Swai AB, Taylor R.
    J Cardiovasc Pharmacol; 1990 Nov; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Nov; 33(8):1185-90. PubMed ID: 6685498
    [Abstract] [Full Text] [Related]

  • 8. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli E.
    Eur J Clin Pharmacol; 1992 Nov; 43(3):219-23. PubMed ID: 1425883
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Nov; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 11. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A, Karádi I, Köszegi G, Pados G, Németh-Csóka M, Pichler M, Romics L.
    Klin Wochenschr; 1990 Nov; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.
    Circulation; 2004 May 11; 109(18):2197-202. PubMed ID: 15123532
    [Abstract] [Full Text] [Related]

  • 15. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI, Bhatnagar D, Durrington PN, Prais H, Haynes B, Morgan J, Borthwick L.
    Eur J Clin Nutr; 1994 Dec 11; 48(12):859-65. PubMed ID: 7889894
    [Abstract] [Full Text] [Related]

  • 16. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
    Levy J, Vandenberg M, Grunberger G.
    Am J Hypertens; 1995 May 11; 8(5 Pt 1):445-53. PubMed ID: 7662219
    [Abstract] [Full Text] [Related]

  • 17. Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
    Hanefeld M, Lang PD, Fischer S, Leonhardt W, Bergmann S, Jaross W.
    Arzneimittelforschung; 1988 Dec 11; 38(12):1835-7. PubMed ID: 3245857
    [Abstract] [Full Text] [Related]

  • 18. [Hemorrheology and quality of life in fibrinogen- and lipid-lowering therapy].
    Walzl M, Lechner H, Walzl B, Kleinert G, Schied G, Freidl W, Bertha G.
    Schweiz Med Wochenschr; 1993 Oct 09; 123(40):1875-82. PubMed ID: 8211041
    [Abstract] [Full Text] [Related]

  • 19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 09; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 20. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC.
    Diabet Med; 1990 Oct 09; 7(8):736-43. PubMed ID: 2147637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.